AR002027A1 - Formulaciones transdermicas y proceso para prepararlas. - Google Patents

Formulaciones transdermicas y proceso para prepararlas.

Info

Publication number
AR002027A1
AR002027A1 ARP960101246A AR10124696A AR002027A1 AR 002027 A1 AR002027 A1 AR 002027A1 AR P960101246 A ARP960101246 A AR P960101246A AR 10124696 A AR10124696 A AR 10124696A AR 002027 A1 AR002027 A1 AR 002027A1
Authority
AR
Argentina
Prior art keywords
formulations
transdermic
prepare
transdermal
transdermal formulation
Prior art date
Application number
ARP960101246A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR002027A1 publication Critical patent/AR002027A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se trata de formulaciones transdérmicas de 3-[4-butiltio)-1,2,5-tiadiazol- 3il]-1-azabiciclo-[2.2.2]octano. La formulación transdérmica de la presenteinvención, proporciona dosis constantes del ingrediente activo, logra una concentración sostenida del agente farmacéuticamente activo en el plasma, ypromueve al paciente a seguir el tratamiento indicado. La invención también se refiere a un proceso para preparar dicha formulación transdérmica.
ARP960101246A 1995-02-17 1996-02-01 Formulaciones transdermicas y proceso para prepararlas. AR002027A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39044595A 1995-02-17 1995-02-17
US48101695A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
AR002027A1 true AR002027A1 (es) 1998-01-07

Family

ID=27013141

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101246A AR002027A1 (es) 1995-02-17 1996-02-01 Formulaciones transdermicas y proceso para prepararlas.

Country Status (22)

Country Link
US (1) US5858393A (es)
EP (1) EP0727208B1 (es)
JP (1) JPH11505513A (es)
KR (1) KR19980702239A (es)
CN (1) CN1181007A (es)
AR (1) AR002027A1 (es)
AU (1) AU700023B2 (es)
BR (1) BR9607722A (es)
CA (1) CA2212874A1 (es)
CO (1) CO4700408A1 (es)
CZ (1) CZ255097A3 (es)
DE (1) DE69614419T2 (es)
ES (1) ES2159683T3 (es)
FI (1) FI973362A0 (es)
HU (1) HUP9802070A3 (es)
IL (1) IL116997A0 (es)
NO (1) NO973715L (es)
NZ (1) NZ302147A (es)
PE (1) PE17897A1 (es)
TR (1) TR199700799T1 (es)
WO (1) WO1996025154A1 (es)
YU (1) YU6196A (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6417227B1 (en) 1999-04-28 2002-07-09 Cg And Associates Methods of delivery of cetyl myristoleate
WO2001030316A2 (en) * 1999-10-28 2001-05-03 3M Innovative Properties Company Transdermal drug delivery devices comprising (r)-(z)-1-azabicyclo(2.2.1)heptan-3-one, 0-(3(3-methoxyphenyl)-2-propynyl)oxime
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US20070264130A1 (en) * 2006-01-27 2007-11-15 Phluid, Inc. Infusion Pumps and Methods for Use
US8986253B2 (en) * 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
AU2009249132B2 (en) * 2008-05-19 2014-07-17 Tandem Diabetes Care Inc. Disposable pump reservoir and related methods
US7943187B2 (en) * 2008-05-23 2011-05-17 Bakr Rabie Paeoniflorin preparations and uses thereof for fat reduction
EP2309993A1 (en) * 2008-06-25 2011-04-20 US Worldmeds LLC Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery
US8408421B2 (en) * 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
EP2334234A4 (en) * 2008-09-19 2013-03-20 Tandem Diabetes Care Inc DEVICE FOR MEASURING THE CONCENTRATION OF A SOLVED SUBSTANCE AND CORRESPONDING METHOD
US9211377B2 (en) * 2009-07-30 2015-12-15 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316893A (en) * 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
IT1233860B (it) * 1988-02-08 1992-04-21 Isf Spa Derivati del peridroazacicloalca (1,2-a) imidazolo ad attivita' nootropa
DK198590D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5238933A (en) * 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions
HU222116B1 (hu) * 1993-08-19 2003-04-28 Novo Nordisk A/S Azabiciklo-tiadiazol- vagy azabiciklo-oxadiazol-származékok alkalmazása antipszichotikus hatású gyógyszerkészítmények előállítására

Also Published As

Publication number Publication date
US5858393A (en) 1999-01-12
WO1996025154A1 (en) 1996-08-22
NZ302147A (en) 1998-10-28
JPH11505513A (ja) 1999-05-21
HUP9802070A3 (en) 2000-09-28
MX9706143A (es) 1997-11-29
CO4700408A1 (es) 1998-12-29
CA2212874A1 (en) 1996-08-22
NO973715D0 (no) 1997-08-12
EP0727208A1 (en) 1996-08-21
PE17897A1 (es) 1997-06-12
DE69614419D1 (de) 2001-09-20
NO973715L (no) 1997-08-12
DE69614419T2 (de) 2002-05-23
AU4774296A (en) 1996-09-04
YU6196A (sh) 1998-09-18
EP0727208B1 (en) 2001-08-16
CZ255097A3 (en) 1997-12-17
IL116997A0 (en) 1996-06-18
FI973362A (fi) 1997-08-15
FI973362A0 (fi) 1997-08-15
BR9607722A (pt) 1998-07-14
CN1181007A (zh) 1998-05-06
ES2159683T3 (es) 2001-10-16
HUP9802070A2 (hu) 1999-02-01
AU700023B2 (en) 1998-12-17
KR19980702239A (ko) 1998-07-15
TR199700799T1 (xx) 1998-02-21

Similar Documents

Publication Publication Date Title
AR002027A1 (es) Formulaciones transdermicas y proceso para prepararlas.
NO952906D0 (no) Farmasöytisk formulering for behandling av nikotinavhengighet
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
ATE269056T1 (de) Hochwirksame dihydroergotaminhaltige arzneizusammensetzungen
ATE311227T1 (de) Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
WO1999040883A3 (en) Compositions and methods for the treatment of cystic fibrosis
IL141515A (en) Optically active pyridyl- 4h - 1, 2, 4 - oxadiazine derivative and its use in the treatment of vascular diseases and pharmaceutical composition comprising same
ES2194899T3 (es) Composicion farmaceutica para administracion transdermica sistemica del principio activo morfina-6-glucuronido.
HUP0301415A2 (hu) Eljárás megnövelt stabilitású egészségvédż termékek formulázására
HUP0100634A2 (hu) Pentaeritrit-tetranitrátot tartalmazó gyógyászati készítmények
NO20034873D0 (no) Bredspektret 2-(amino)-benzoxazolsulfonamid HIV proteasehemmere
Nolling Non-Traumatic Removal of the Nail and Simultaneous Treatment of Onychomycosis
KR920700041A (ko) 치료화합물과 그의 조성 및 용도
CO4480761A1 (es) Metodo para movilizar celulas tronco hematopoyeticas
CA2021501A1 (en) Topical pharmaceutical compositions
GEP20012366B (en) Thienyl-, Furil-, Pyrrolyl- and Biphenyl-Sulfonamides, Their Derivatives, Their Use in Medicinal Purposes, Pharmaceutical Composition Containing the Same and Method for Treatment

Legal Events

Date Code Title Description
FA Abandonment or withdrawal